Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 13/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294443 | 0.89 | SORD (0.48) | SORDALDH1A1MEN1GAAKMT2A | |
| SCHEMBL6298062 | 0.89 | SORD (0.48) | SORDALDH1A1MEN1GAAKMT2A | |
| SCHEMBL6298857 | 0.88 | SORD (0.54) | SORDHCRTR1HCRTR2 | |
| SCHEMBL6293089 | 0.86 | SORD (0.41) | SORD | |
| SCHEMBL6294684 | 0.85 | SORD (0.49) | SORDALDH1A1MEN1GAAKMT2A | |
| SCHEMBL7489299 | 0.85 | SORD (0.53) | SORD | |
| SCHEMBL6297961 | 0.83 | SORD (0.52) | SORD | |
| SCHEMBL6822775 | 0.83 | SORD (0.67) | SORDDPP4DPP8 | |
| SCHEMBL6293141 | 0.81 | SORD (0.40) | SORD | |
| SCHEMBL6294631 | 0.81 | SORD (0.39) | SORDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936600-B2 | Sorbitol dehrydrogenase inhibitors | PFIZER INC (US) | 2005-08-30 | — | — | US | disclosed |
| US-6869943-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC (US) | 2005-03-22 | — | — | US | disclosed |
| US-20050020578-A1 | Sorbitol dehydrogenase inhibitors | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2004-04-22 | — | — | US | disclosed |
| US-6660740-B1 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-12-09 | — | — | US | disclosed |
| US-6602875-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-08-05 | — | — | US | disclosed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | disclosed |
| US-6414149-B1 | TREATING DIABETES, TREATING OR PREVENTING DIABETIC COMPLICATIONS | PFIZER INC. | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020578-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | SORD 2/4885ALDH1A1 26/4885MEN1 1554/4885 |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | SORD 2/4885ALDH1A1 25/4885MEN1 1642/4885 |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | SORD 2/4885ALDH1A1 25/4885MEN1 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.